Tumores Torácicos

Estudo randomizado | Sugemalimabe melhora a sobrevida livre de progressão vs. placebo em pacientes com câncer metastático de pulmão de não pequenas células.

4 Fev, 2022 | 14:36h

Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial – The Lancet Oncology (link para o resumo – $ para o texto completo)

Estudo relacionado: Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial – The Lancet Oncology (link para o resumo – $ para o texto completo)

Comentários:

Sugemalimab shows promise for locally advanced, metastatic NSCLC – Medicine Matters

Sugemalimab Boosts Outcomes in NSCLC – MedPage Today (necessário cadastro gratuito)

 

Comentário no Twitter

In the phase III GEMSTONE-302 trial of chemo + sugemalimab or placebo in 479 with untreated advanced-stage NSCLC, mPFS was 9.0 vs 4.9 months (HR 0.48; P<0.0001); OS was 72.4% vs 62.0% at 12 months & 47.1% vs 38.1% at 24 months (HR 0.67, 95% CI 0.50–0.90): https://t.co/z6f00tqy8B

— NatureRevClinOncol (@NatRevClinOncol) January 19, 2022

 

---

Revisão sistemática | Imunoterapia (exceto “checkpoint inhibitors”) para câncer de pulmão de não pequenas células estágios I a III tratado com cirurgia ou radioterapia com intenção curativa.

28 Jan, 2022 | 15:50h

Immunotherapy (excluding checkpoint inhibitors) for stage I to III non‐small cell lung cancer treated with surgery or radiotherapy with curative intent – Cochrane Library

---

Diretriz ASCO | Tratamento do câncer de pulmão não pequenas células estágio III.

20 Jan, 2022 | 20:34h

Management of Stage III Non–Small-Cell Lung Cancer: ASCO Guideline – Journal of Clinical Oncology

---

Estudo randomizado | Radioterapia pós-cirúrgica não aumentou a sobrevida livre de doença em pacientes com câncer de pulmão não pequenas células completamente ressecado com envolvimento N2 mediastinal comprovado.

10 Jan, 2022 | 11:51h

Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial – The Lancet Oncology (link para o resumo – $ para o texto completo)

Comentários:

Postoperative Radiotherapy for Patients With Completely Resected Stage IIIA NSCLC and N2 Involvement – The ASCO Post

Post-Operative Radiotherapy Not Tied to Better Disease-Free Survival in NSCLC – MedPage Today (gratuito por tempo limitado)

---

Mesotelioma pleural maligno: Diretrizes de Prática Clínica da ESMO para diagnóstico, tratamento e seguimento.

8 Dez, 2021 | 12:57h

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up – Annals of Oncology

---

Diretriz CHEST | Rastreamento para câncer de pulmão.

29 Nov, 2021 | 10:56h

Resumo executivo: Screening for Lung Cancer: Chest Guideline and Expert Panel Report

Diretriz completa: Screening for Lung Cancer: CHEST Guideline and Expert Panel Report

Comunicado de imprensa: CHEST releases expert guidelines for lung cancer screening – Elsevier

Conteúdos relacionados:

USPSTF Statement: begin screening for lung cancer at age 50 years instead of 55 years for patients at risk

Meta-analysis: Lung cancer screening using low-dose computed tomography reduces lung cancer–specific mortality, albeit with a tradeoff of likely overdiagnosis

 

Comentário no Twitter

CHEST Guidelines and Expert Panel Report contains 16 evidence-based recommendations for the benefits, harms, and implementation of low-dose chest computed tomography (CT) screening. https://t.co/4mvjEOftQl #CHESTOnc #CHESTGuidelines #LungCancerAwarenessMonth pic.twitter.com/uyh9Pf0s5s

— CHEST® Journal (@journal_CHEST) November 23, 2021

 

---

Compreendendo uma doença complexa: abordagem prática do manejo de tumores neuroendócrinos.

9 Nov, 2021 | 12:00h

Making Sense of a Complex Disease: A Practical Approach to Managing Neuroendocrine Tumors – JCO Oncology Practice

 

Comentário no Twitter

#Neuroendocrine tumors are heterogeneous with a complex treatment landscape. This #JCOOP Clinical Review discusses optimal management of #NET and key patient/tumor characteristics that can guide treatment selection https://t.co/zZF36E93w8 pic.twitter.com/2xqwOlwIvw

— Journal of Clinical Oncology (@JCO_ASCO) October 28, 2021

 

---

Estudo randomizado | Nivolumabe vs. placebo em pacientes com mesotelioma maligno recidivante.

21 Out, 2021 | 11:10h

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial – The Lancet Oncology

 

Comentário no Twitter

CONFIRM Trial: a phase III study demonstrated longer PFS and OS with Nivolumab compared with Placebo in patients with Pleural or Peritoneal Malignant Mesothelioma who have progressed following platinum-based chemotherapy @OncoAlert #LCSM https://t.co/jKoKXEXgpB

— Dipesh Uprety MD FACP (@dipeshuprety4) October 15, 2021

 

---

Posicionamento científico sobre a ablação percutânea do câncer pulmonar de células não pequenas e doenças metastáticas para os pulmões.

8 Out, 2021 | 12:15h

Society of Interventional Radiology Multidisciplinary Position Statement on Percutaneous Ablation of Non-small Cell Lung Cancer and Metastatic Disease to the Lungs – Journal of Vascular and Interventional Radiology

Comentário: Society of Interventional Radiology issues guidance for minimally invasive lung cancer treatments – Health Imaging

---

Diretriz ESMO | Câncer de pulmão de células não pequenas precoce e localmente avançado.

14 Set, 2021 | 14:09h

Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy – Annals of Oncology

---